Do analysts prefer AADI or LRMR?

Larimar Therapeutics has a consensus price target of $11.86, suggesting a potential upside of 279.19%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00

Do analysts rate DMAC or AADI?

DiaMedica Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 52.89%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate AADI or MYGN?

Myriad Genetics has a consensus target price of $3.12, suggesting a potential downside of 25.80%. Given Myriad Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Myriad Genetics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Myriad Genetics 3 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.57

Do analysts recommend AADI or ARTV?

Artiva Biotherapeutics has a consensus target price of $39.00, indicating a potential upside of 457.22%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Do analysts rate BNTC or AADI?

Benitec Biopharma currently has a consensus price target of $24.00, indicating a potential upside of 150.81%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Benitec Biopharma is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Aadi Bioscience (AADI) Competitors

$3.86 +0.04 (+1.05%)

As of 09/24/2026

Compare

AADI vs. LRMR, DMAC, MYGN, ARTV, and BNTC

Should you buy Aadi Bioscience stock or one of its competitors? Aadi Bioscience's main competitors and comparable companies include Larimar Therapeutics (LRMR), DiaMedica Therapeutics (DMAC), Myriad Genetics (MYGN), Artiva Biotherapeutics (ARTV), and Benitec Biopharma (BNTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aadi Bioscience compare to Larimar Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Aadi Bioscience has higher revenue and earnings than Larimar Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.80	-$65.76M	-$2.35	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Larimar Therapeutics has a consensus price target of $11.86, suggesting a potential upside of 279.19%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Larimar Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Larimar Therapeutics and 0 mentions for Aadi Bioscience. Larimar Therapeutics' average media sentiment score of 1.79 beat Aadi Bioscience's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Larimar Therapeutics	Very Positive

Summary

Larimar Therapeutics beats Aadi Bioscience on 11 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

DiaMedica Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

DiaMedica Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 52.89%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, DiaMedica Therapeutics had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for DiaMedica Therapeutics and 0 mentions for Aadi Bioscience. DiaMedica Therapeutics' average media sentiment score of 1.04 beat Aadi Bioscience's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
DiaMedica Therapeutics	Positive
Aadi Bioscience	Neutral

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

DiaMedica Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

DiaMedica Therapeutics has higher earnings, but lower revenue than Aadi Bioscience. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Aadi Bioscience	$25.07M	3.80	-$65.76M	-$2.35	N/A

Summary

DiaMedica Therapeutics beats Aadi Bioscience on 9 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Myriad Genetics?

Aadi Bioscience (NASDAQ:AADI) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Myriad Genetics has a consensus target price of $3.12, suggesting a potential downside of 25.80%. Given Myriad Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Myriad Genetics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57

In the previous week, Myriad Genetics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Myriad Genetics and 0 mentions for Aadi Bioscience. Myriad Genetics' average media sentiment score of 0.35 beat Aadi Bioscience's score of 0.00 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Myriad Genetics	Neutral

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Aadi Bioscience has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.80	-$65.76M	-$2.35	N/A
Myriad Genetics	$824.50M	0.49	-$365.90M	-$1.19	N/A

Myriad Genetics has a net margin of -13.96% compared to Aadi Bioscience's net margin of -246.06%. Myriad Genetics' return on equity of -16.09% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Myriad Genetics	-13.96%	-16.09%	-8.10%

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 1.9% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Myriad Genetics beats Aadi Bioscience on 11 of the 15 factors compared between the two stocks.

How does Aadi Bioscience compare to Artiva Biotherapeutics?

Aadi Bioscience (NASDAQ:AADI) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Aadi Bioscience has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.80	-$65.76M	-$2.35	N/A
Artiva Biotherapeutics	$250K	1,368.72	-$83.86M	-$3.30	N/A

Artiva Biotherapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Artiva Biotherapeutics' return on equity of -53.86% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

In the previous week, Artiva Biotherapeutics had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Artiva Biotherapeutics and 0 mentions for Aadi Bioscience. Artiva Biotherapeutics' average media sentiment score of 0.64 beat Aadi Bioscience's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Artiva Biotherapeutics	Positive

Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Artiva Biotherapeutics has a consensus target price of $39.00, indicating a potential upside of 457.22%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Artiva Biotherapeutics beats Aadi Bioscience on 11 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Benitec Biopharma has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Benitec Biopharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Benitec Biopharma's return on equity of -28.41% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-28.41%	-27.76%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Benitec Biopharma has higher earnings, but lower revenue than Aadi Bioscience. Benitec Biopharma is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$45.55M	-$0.98	N/A
Aadi Bioscience	$25.07M	3.80	-$65.76M	-$2.35	N/A

Benitec Biopharma currently has a consensus price target of $24.00, indicating a potential upside of 150.81%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Benitec Biopharma is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Benitec Biopharma had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Benitec Biopharma and 0 mentions for Aadi Bioscience. Benitec Biopharma's average media sentiment score of 0.41 beat Aadi Bioscience's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Benitec Biopharma	Neutral
Aadi Bioscience	Neutral

Summary

Benitec Biopharma beats Aadi Bioscience on 11 of the 15 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.33M	$3.92B	$7.26B	$13.15B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-1.69	14.08	274.71	25.82
Price / Sales	3.80	1,320.94	681.56	110.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.90	15.31	10.46	6.32
Net Income	-$65.76M	-$22.86M	$3.49B	$359.77M
7 Day Performance	-5.39%	-2.91%	-1.23%	-0.10%
1 Month Performance	-20.90%	-9.00%	-4.49%	-4.01%
1 Year Performance	102.09%	31.63%	16.46%	6.23%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$3.86 +1.0%	N/A	+99.0%	$95.33M	$25.07M	N/A	40
LRMR Larimar Therapeutics	3.7887 of 5 stars	$3.82 -0.3%	$11.86 +210.4%	-34.9%	$397.87M	N/A	N/A	71	News Coverage Positive News
DMAC DiaMedica Therapeutics	2.1253 of 5 stars	$7.78 +7.2%	$12.00 +54.2%	+14.3%	$391.50M	N/A	N/A	35	Positive News High Trading Volume
MYGN Myriad Genetics	0.6783 of 5 stars	$4.02 +0.2%	$3.12 -22.4%	-46.4%	$383.55M	$824.50M	N/A	2,700
ARTV Artiva Biotherapeutics	2.6126 of 5 stars	$8.09 +3.3%	$39.00 +382.1%	+160.1%	$382.81M	$250K	N/A	115

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. LRMR, DMAC, MYGN, ARTV, and BNTC

How does Aadi Bioscience compare to Larimar Therapeutics?

Summary

How does Aadi Bioscience compare to DiaMedica Therapeutics?

Summary

How does Aadi Bioscience compare to Myriad Genetics?

Summary

How does Aadi Bioscience compare to Artiva Biotherapeutics?

Summary

How does Aadi Bioscience compare to Benitec Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. LRMR, DMAC, MYGN, ARTV, and BNTC

How does Aadi Bioscience compare to Larimar Therapeutics?

Which has preferable earnings and valuation, AADI or LRMR?

Do analysts prefer AADI or LRMR?

Is AADI or LRMR more profitable?

Which has more volatility & risk, AADI or LRMR?

Do insiders and institutionals have more ownership in AADI or LRMR?

Does the media favor AADI or LRMR?

Summary

How does Aadi Bioscience compare to DiaMedica Therapeutics?

Is DMAC or AADI more profitable?

Do analysts rate DMAC or AADI?

Does the media prefer DMAC or AADI?

Do insiders & institutionals hold more shares of DMAC or AADI?

Which has more risk and volatility, DMAC or AADI?

Which has higher valuation and earnings, DMAC or AADI?

Summary

How does Aadi Bioscience compare to Myriad Genetics?

Do analysts rate AADI or MYGN?

Does the media favor AADI or MYGN?

Which has more risk & volatility, AADI or MYGN?

Which has better earnings & valuation, AADI or MYGN?

Is AADI or MYGN more profitable?

Do institutionals and insiders believe in AADI or MYGN?

Summary

How does Aadi Bioscience compare to Artiva Biotherapeutics?

Which has better valuation & earnings, AADI or ARTV?

Is AADI or ARTV more profitable?

Does the media prefer AADI or ARTV?

Which has more volatility & risk, AADI or ARTV?

Do institutionals & insiders have more ownership in AADI or ARTV?

Do analysts recommend AADI or ARTV?

Summary

How does Aadi Bioscience compare to Benitec Biopharma?

Which has more volatility and risk, BNTC or AADI?

Is BNTC or AADI more profitable?

Which has better earnings & valuation, BNTC or AADI?

Do analysts rate BNTC or AADI?

Do insiders & institutionals have more ownership in BNTC or AADI?

Does the media favor BNTC or AADI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools